RET M918T mutation (MEN2B / sporadic MTC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-RET-M918T |
|---|---|
| Type | Biomarker |
| Aliases | RET M918TМутація RET M918T (MEN2B / спорадичний МРЩЗ) |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-THYROID-2025 |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Mutation details | {"exon": "16", "functional_impact": "activating; intracellular kinase domain — constitutive RET dimerization-independent activation", "gene": "RET", "hgvs_protein": "p.M918T", "variant_type": "missense"} |
| Measurement | MethodGermline NGS (MEN2 panel) for hereditary screening; tumor NGS for sporadic MTC Unitscategorical (positive | negative) |
| Actionability lookup | {"gene": "RET", "variant": "M918T"} |
| Related biomarkers | BIO-RET |
Notes
Most aggressive RET mutation. Germline → MEN2B (multiple endocrine neoplasia type 2B) — defines need for prophylactic thyroidectomy before age 1. Sporadic in ~25% of MTC, associated with poorer prognosis. Selpercatinib (Retsevmo) and pralsetinib (Gavreto) — selective RET inhibitors; LIBRETTO-001 ORR ~60-70% in advanced MTC. Replaced multikinase inhibitors (vandetanib, cabozantinib) as 1L systemic therapy in actionable RET-altered advanced MTC.
Used By
Red flag
RF-MTC-HIGH-RISK-BIOLOGY- Medullary thyroid carcinoma with actionable RET mutation: germline RET M918T (MEN2B — mos...